The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus.

Leng, Weiling; Wu, Mingxia; Pan, Hang; Lei, Xiaotian; Chen, Liu; Wu, Qinan; Ouyang, Xinshou; Liang, Ziwen

Leng, Weiling; Wu, Mingxia; Pan, Hang; Lei, Xiaotian; Chen, Liu; Wu, Qinan; Ouyang, Xinshou; Liang, Ziwen.

Afiliación

Leng W; Department of Endocrinology, Southwest Hospital, the Third Military Medical University (Army Medical University), Chongqing 400038, China.
Wu M; Health Management Center, Southwest Hospital, the Third Military Medical University (Army Medical University), Chongqing 400038, China.
Pan H; Department of Endocrinology, Southwest Hospital, the Third Military Medical University (Army Medical University), Chongqing 400038, China.
Lei X; Department of Endocrinology, Southwest Hospital, the Third Military Medical University (Army Medical University), Chongqing 400038, China.
Chen L; Department of Endocrinology, Southwest Hospital, the Third Military Medical University (Army Medical University), Chongqing 400038, China.
Wu Q; Department of Endocrine Nephropathy, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing 400038, China.
Ouyang X; Section of Digestive Diseases, Yale University of Medicine, New Haven, CT, USA.
Liang Z; Department of Endocrinology, Southwest Hospital, the Third Military Medical University (Army Medical University), Chongqing 400038, China.

Ann Transl Med ; 7(18): 429, 2019 Sep.

Article en En | MEDLINE | ID: mdl-31700865

Palabras clave

Dapagliflozin (DAPA); NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome; reactive oxygen species (ROS); steatohepatitis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Transl Med Año: 2019 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google